VR Logo

Dyne Therapeutics Inc. (DYN) download report


Healthcare | Biotechnology & Pharma Research

Dyne Therapeutics Inc. (DYN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.

IPO Date: 17-Sep-2020

CEO, Pres & Director: Mr. Joshua T. Brumm

Chief Operating Officer: Ms. Susanna Gatti High M.B.A.

Listing: NASDAQ: DYN

Country: United States

Headquarters: Waltham, MA

Website: https://www.dyne-tx.com

Key Facts

Market cap: $371.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-124.32 Mln

Cash: $323.15 Mln

Total Debt: $32.78 Mln

Insider's Holding: 1.53%

Liquidity: Low

52 Week range: $4.30 - 21.63

Shares outstanding: 51,653,500

10 Years Aggregate:

  • CFO: $1,241.93 Mln
  • EBITDA: $2,428.31 Mln
  • Net Profit: $-1,678.40 Mln

Stock Performance

Time Period Dyne Therapeutics (DYN) S&P BSE Sensex S&P Small-Cap 600
YTD-30.03-7.86-19.79
1 month81.66-3.75-9.59
3 months-20.46-10.80-13.28
1 Year-60.831.50-17.92
3 Years--10.755.46
5 Years--11.435.57
10 Years--11.849.48
As on 06-Jul-2022
Year Dyne Therapeutics (DYN) S&P Small-Cap 600 S&P BSE Sensex
2021-43.3825.2721.99